Sign Up Now
Get instant access to over 1 million+ study documents
OR
Already registered? click here to login
By creating your account, you agree to our terms of service, privacy policy and student honor code.
Though also quite controversial due to the environmental degradation that is created by any industrial interest in the natural world, pharmaceutical researchers are increasingly turning to plants and other naturally created compounds for the development of new pharmaceuticals (Newman & Cragg 2007). As research continues into this relatively new and unexamined area of pharmaceutical potential, it is likely that many profound new discoveries will be made.
One particular piece of research that examined twenty-five years' worth of empirical and primary research in the area of naturally derived pharmaceuticals and pharmaceutical compounds came to some startling conclusions. Though plants have been a major source of chemicals used in a variety of human industries, including in the pharmaceutical industry, these researchers concluded that is microbial interactions taking place on host plants in their natural settings that is often the source of the desired compounds rather then their having been derived directly from or by the plant itself (Newman & Cragg 2007). This assertion is not entirely new, but it is made most compelling by the extent to which these researchers are able to provide details supporting this theory and indeed points to an exciting new area of pharmaceutical and environmental research that is truly at the heart of many scientific discourse communities, including the pharmaceutical community.
Personal Intersection
My own personal interests have long included a desire to improve man's relationship with and indeed as a part of nature. This does not have to include a giving up of the many luxuries and amenities with which mankind has adorned itself often at the expense of nature, but rather I am interested in discovering how man can benefit from nature without destroying it. There is a definite place for this interest in man's symbiosis with nature in the pharmaceutical discourse community, as indeed the discovery of new pharmaceutical compounds relies quite heavily on the preservation...
Learning more about how various natural compounds are formed and preserving the environment and organisms that produce compounds currently recognized as useful by the pharmaceutical industry would show a clear benefit to mankind as well as to nature, thus remaining in keeping with my overriding belief that man's benefit need not come at he cost of nature's degradation. These research areas would be of a great deal of interest to me as I further pursue my knowledge of the pharmaceutical world in general and of the pharmaceutical discourse community specifically.
Conclusion
The pharmaceutical discourse community is itself a broad and diverse community with many smaller communities yet a great deal of overlap in the linguistic codes and discourse areas between them. Becoming a part of this large and diverse discourse community is at once encouraging and slightly overwhelming; there is such a wealth of information and a plethora of research areas involved in developing pharmaceutical knowledge that a narrow focus can seem at times impossible. The above discussion and specific areas of focus help to narrow the field of discourse in which this researcher hopes to become more permanently engaged.
References
Humer, F. (2005). Innovation in the Pharmaceutical Industry -- Future Prospects. Zu-rcher Volkswirtschaftliche Gesellschaft. Accessed 27 November 2010. www.roche.com/fbh_zvg05_e.pdf
Newman, D. & Cragg, G. (2007). Natural Products as Sources of New Drugs over the Last 25 Years. Journal of Natural Products 70(3), pp. 461-77.
Participants filled out a Short-Form McGill Questionnaire, an Arthritis Self-Efficacy Scale, and Fibromyalgia Impact Questionnaire in order to measure their levels of pain over the past few weeks. What the researchers found through statistical analysis was self-management strategies that reduced pain over time were most effective in the group that was exposed to guided imagery techniques. The level of guided imagery therapy was not itself significant, but more of
UK Healthcare Within this section of Chapter One, a historical perspective of NHS will be provided. This discussion will identify problem areas that have emerged in relation to NHS with an attempt made to address the manner in which such problems have historically influenced reform efforts. With the passage and associated provisions of the NHS Act of 1946, NHS was implemented in the UK in 1948. The NHS Act of 1946 served
Pharmaceutical Ethics Issues Generally, business ethics is a concept that has not been upheld or exemplified to any high standard by the modern pharmaceutical industry. It is an industry frequently plagued by unethical marketing decisions and practices, the pursuit of business strategies and policies that violate public trust in spirit if not necessarily in the written word, and that has embraced research practices that are sometimes highly questionable. In the modern
CPOE primary use to manage cost and quality in the physician and pharmacy interaction? An electronic process that enables providers of health care to manage the results of orders entered in to a computer electronically is known as Computer Provider Order Enter or CPOE. In line with the reports of Institute of Medicine (IOM) titled, "To Err is Human: Building a Safer Health System and Crossing the Quality Chasm: A
Figure 1 portrays the state of Maryland, the location for the focus of this DRP. Figure 1: Map of Maryland, the State (Google Maps, 2009) 1.3 Study Structure Organization of the Study The following five chapters constitute the body of Chapter I: Introduction Chapter II: Review of the Literature Chapter III: Methods and Results Chapter IV: Chapter V: Conclusions, Recommendations, and Implications Chapter I: Introduction During Chapter I, the researcher presents this study's focus, as it relates to the
Gross Profitability and Pharmaceutical R&D Spending Are the pharmaceutical companies - as they claim to be doing - re-investing their substantial profits into research and development for better, more patient-friendly and badly-needed medicines? Or, do the pharmaceutical firms just use that explanation to justify raking in huge profits at the expense of the already-financially-strapped consumer? Those are the questions asked - and answered, to a certain degree - in the